case_images: PMC11818870_01
case_images: (a-c) Erythematous-violaceous hyperkeratotic plaques with poorly defined margins localized to the backs of the hands, buttocks, and lower limbs before initiating therapy with risankizumab. (d-f) Residual hyperpigmentation observed after six months of therapy.
case_images: jcm-14-00796-g001.jpg
case_images: PMC11818870_01_jcm-14-00796-g001.jpg
case_images: jcm-14-00796-f001
case_images: However, treatment was discontinued due to the emergence of diffuse erythematous-squamous plaques predominantly localized to the buttocks and lower limbs, including the involvement of the hands (Figure 1a-c). After six months, the patient achieved a PGA of 1, a BSA of 3%, and a DLQI of 2, with residual involvement localized only to the backs of the hands (Figure 1d-f).
case_images: PMC11818870_02
case_images: (a) Diffuse facial erythema with fine scaling observed before the initiation of therapy. (b) Clinical improvement with faint residual erythema after three months of risankizumab.
case_images: jcm-14-00796-g002.jpg
case_images: PMC11818870_02_jcm-14-00796-g002.jpg
case_images: jcm-14-00796-f002
case_images: In September 2023, he developed a psoriasiform dermatitis condition involving the face (Figure 2a), upper limbs, and lower limbs. After three months of the treatment, the patient showed significant improvement, with a reduction in PGA from 3 to 1, BSA from 15% to 3%, and DLQI from 10 to 2, achieving complete skin clearance at six months (Figure 2b).
case_images: PMC11818870_03
case_images: (a,c) Psoriasiform dermatitis of palms and soles before initiating therapy. (b,d) Complete resolution of cutaneous manifestations after six weeks of therapy.
case_images: jcm-14-00796-g003.jpg
case_images: PMC11818870_03_jcm-14-00796-g003.jpg
case_images: jcm-14-00796-f003
case_images: By October 2024, while the eczema on his back had improved, he developed a psoriasiform condition affecting the palms and the soles (Figure 3a,c). Six weeks later, the patient showed complete resolution of the eczematous areas on the trunk and an initial improvement in the palmoplantar regions (Figure 3b,d).
case_images: PMC11818870_04
case_images: (a,c) Eczematous erythrodermic dermatitis with lamellar desquamation after two months of bimekizumab treatment. (b,d) Resolution of dermatitis after three months of abrocitinib therapy.
case_images: jcm-14-00796-g004.jpg
case_images: PMC11818870_04_jcm-14-00796-g004.jpg
case_images: jcm-14-00796-f004
case_images: After less than two months, the patient presented to our clinic with erythrodermic eczematous dermatitis (Figure 4a,c). After three months of therapy, the BSA had further decreased to 3%, the PGA had improved from 4 before starting abrocitinib to 1, and the DLQI had decreased from 25 to 2 (Figure 4b,d).
case_images: PMC11818870_05